Carboplatin and Paclitaxel for Small Cell Lung Cancer
Author Information
Author(s): Gridelli C, Manzione L, Perrone F, Veltri E, Cioffi R, Caprio M Grazia, Frontini L, Rossi A, Barletta E, Barzelloni M L, Bilancia D, Gallo C
Primary Institution: Istituto Nazionale Tumori, Naples
Hypothesis
The study aims to test the efficacy and toxicity of carboplatin plus paclitaxel in treating extensive small cell lung cancer.
Conclusion
Carboplatin plus paclitaxel is well tolerated but not effective enough to proceed to a phase 3 trial.
Supporting Evidence
- 48 patients were enrolled in the study.
- 3 patients had a complete response and 23 had a partial response.
- The overall response rate was 54.2%.
- Median time to progression was 5.7 months.
- Median survival was 9.6 months.
Takeaway
This study tested a combination of two cancer drugs on patients with a specific type of lung cancer, and while the patients handled the treatment well, it didn't work well enough to continue testing.
Methodology
A multicentre phase 2 trial with a single-stage design was conducted to evaluate the treatment.
Limitations
The treatment was not sufficiently active to warrant further testing in a phase 3 trial.
Participant Demographics
Median age of participants was 59 years.
Statistical Information
Confidence Interval
95% CI: 39.2–68.6
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website